Baltimore, MDNCT04248569Now EnrollingIRB Ready

Fibrolamellar Hepatocellular Carcinoma (FLC) Clinical Trial in Baltimore, MD

Access cutting-edge fibrolamellar hepatocellular carcinoma (flc) treatment through this clinical trial at a research site in Baltimore. Study-provided care at no cost to qualified participants.

Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Quick Self-Assessment

See if you qualify for this Baltimore location

Preparing your pre-screening questions…

Expert Care in Baltimore

Access fibrolamellar hepatocellular carcinoma (flc) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related fibrolamellar hepatocellular carcinoma (flc) treatment provided free

Apply for This Baltimore Location

Check if you qualify for this fibrolamellar hepatocellular carcinoma (flc) clinical trial in Baltimore, MD

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Baltimore

    Convenient for MD residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Baltimore site if eligible
  4. 4Begin participation

About This Fibrolamellar Hepatocellular Carcinoma (FLC) Study in Baltimore

The primary objective of the trial is the safety and tolerability of administering a vaccine targeting the DNAJB1-PRKACA fusion kinase, in combination with nivolumab and ipilimumab in patients with unresectable or metastatic FLC and with non-FLC solid tumors and to assess the T-cell response.

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Who Can Participate

Inclusion Criteria

for Cohort A, B and C:
Cohort A and B: Must have histologically confirmed FLC (fibrolamellar hepatocellular cancer) that is metastatic or unresectable.
Cohort C: Patients with histologically proven metastatic or unresectable DNAJB1-PRKACA fusion transcript positive solid tumor malignancies, non-FLC solid tumors.
Cohort A and B: Age \> 12 years. Note: Subjects age \> 12 years but \<18 are eligible to enroll only after 6 adult patients have enrolled on the study.
Cohort A and B: Patients \< 18 years old must have a body weight ≥40 kg.
Cohort C: Patients must be Age ≥ 18 years. All Cohorts:
Presence of DNAJB1-PRKACA fusion transcript, assessed by RNA-sequencing, DNA-sequencing, or in situ hybridization in the archival tissue.
ECOG performance status of ≤2 (Karnofsky ≥60%)
Patients must have adequate liver, kidney and marrow function defined by study-specified laboratory tests prior to initial study drug.
Patients must have measurable disease per RECIST 1.1.
Must be willing to provide tissue and blood samples for mandatory translational research.
Woman of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol.
Men must use acceptable form of birth control while on study.
Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria

for Cohorts A, B and C:
Cohort A and C: Patients with a history of prior treatment with checkpoint inhibitors, such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-OX-40, anti-CD40, anti-CTLA-4, or anti-LAG-3 antibodies. NOTE: Prior therapy with interferon-alpha is allowed.
Cohort B: Participants a with history of unacceptable, life-threatening toxicity related to prior immune therapy (eg, anti-CTLA-4 or anti-PD-1/PD-L1 treatment, any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) except those that are unlikely to re-occur with standard countermeasures (eg, hormone replacement after endocrinopathy). All Cohorts:
Have had chemotherapy or other systemic therapy or radiotherapy, as follows:
Have had chemotherapy, biological cancer therapy, or radiation 14 days prior to the first dose of study drug.
Have had surgery within 28 days of dosing of investigational agent, excluding minor procedures (dental work, skin biopsy, etc.), celiac plexus block, and biliary stent placement.
Have received other approved or investigational agents or device within 28 days of the first dose of study drug.
Have not recovered from acute adverse events to grade ≤1 or baseline due to agents administered.
Have received any non-oncology live vaccine therapy used for prevention of infectious diseases within 28 days of study treatment
Known sensitivity to or history of allergic reactions to investigational drug (s).
Hypersensitivity reaction to any monoclonal antibody.
Has active autoimmune disease that has required systemic treatment in the past 2 years, or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents.
Presence of any tissue or organ allograft, regardless of need for immunosuppression, including corneal allograft. Patients with a history of allogeneic hematopoeitic stem cell transplant will be excluded.
Has a diagnosis of immunodeficiency.
Systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalents) or other immunosuppressive medications within 7 days of study drug administration.
Symptomatic interstitial lung disease.
Has a pulse oximetry of \<92% on room air or is on supplemental home oxygen.
Active or untreated brain metastases or leptomeningeal metastases.
Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.
Are pregnant or breastfeeding.
Infection with HIV or hepatitis B or C.
Have had evidence of active or acute diverticulitis, intra-abdominal abscess, or GI obstruction.
Unwilling or unable to follow the study schedule for any reason.
Any other sound medical, psychiatric, and/or social reason as determined by the Investigator.
Any illicit drugs or other substance abuse.
Clinically meaningful ascites. Inclusion Criteria for Re-Enrolling Patients:
Patients previously treated with the vaccine targeting the DNAJB1-PRKACA fusion kinase in combination with nivolumab and ipilimumab, who, in the opinion of the principal investigator, had clinical or radiological benefits.
Patients \< 18 years old must have a body weight ≥40 kg.
ECOG performance status of ≤2 (Karnofsky ≥60%, see Appendix A).
Patients must have adequate liver, kidney and marrow function defined by study-specified laboratory tests prior to initial study drug.
Patients must have measurable disease per RECIST 1.1.
Willingness to provide tissue and blood samples for mandatory translational research.
Woman of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol.
Men must use acceptable form of birth control while on study.
Ability to understand and willingness to sign a written informed consent document. Exclusion Criteria for Re-Enrolling Patients:
Participants with a history of prior unacceptable and/or life-threatening toxicities.
Patients who have had chemotherapy or other systemic therapy or radiotherapy, as follows:
Patients who have had chemotherapy, biological cancer therapy, or radiation 14 days prior to the first dose of study drug.
Patients who have had surgery within 28 days of dosing of investigational agent, excluding minor procedures (dental work, skin biopsy, etc.), celiac plexus block, and biliary stent placement.
Patients who have received other approved or investigational agents or device within 28 days of the first dose of study drug.
Patients who have not recovered from acute adverse events to grade ≤1 or baseline due to agents administered, with exception of alopecia or stable neuropathy, unless approved by the IND Sponsor.
Patients who have received any non-oncology live vaccine therapy used for prevention of infectious diseases within 28 days of study treatment.
Known sensitivity to or history of allergic reactions to investigational drug (s).
Hypersensitivity reaction to any monoclonal antibody.
Has active autoimmune disease that has required systemic treatment in the past 2 years, or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents.
Has active autoimmune disease that has required systemic treatment in the past 2 years, or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents.
Presence of any tissue or organ allograft, regardless of need for immunosuppression, including corneal allograft. Patients with a history of allogeneic hematopoeitic stem cell transplant will be excluded.
Has a diagnosis of immunodeficiency.
Systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalents) or other immunosuppressive medications within 7 days of study drug administration.
Symptomatic interstitial lung disease.
Has a pulse oximetry of \<92% on room air or is on supplemental home oxygen.
Active or untreated brain metastases or leptomeningeal metastases.
Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.
Are pregnant or breastfeeding.
Infection with HIV or hepatitis B or C.
Have had evidence of active or acute diverticulitis, intra-abdominal abscess, or GI obstruction.
Unwilling or unable to follow the study schedule for any reason.
Any other sound medical, psychiatric, and/or social reason as determined by the Investigator.
Any illicit drugs or other substance abuse.
Clinically meaningful ascites.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Baltimore?

Yes, this clinical trial (NCT04248569) has an active research site in Baltimore, MD that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Fibrolamellar Hepatocellular Carcinoma (FLC) Treatment Options in Baltimore, MD

If you're searching for fibrolamellar hepatocellular carcinoma (flc) treatment options in Baltimore, MD, this clinical trial (NCT04248569) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Baltimore research site is actively enrolling participants for this clinical trial. You'll receive care from experienced fibrolamellar hepatocellular carcinoma (flc) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all fibrolamellar hepatocellular carcinoma (flc) clinical trials near you to find additional studies recruiting in your area.

More Liver Cancer Trials in Baltimore, MD

See all liver cancer clinical trials recruiting in Baltimore — not just this study.

Browse Liver Cancer Trials in Baltimore →

Browse More Trials by Condition

Liver Cancer TrialsFollicular Lymphoma TrialsFibromyalgia TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Baltimore?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Baltimore, MD